Ferring Pharmaceuticals 보도자료
01월 11일 19:25
- Ferring and the Chinese Academy of Sciences Collaborate to Advance Research in Reproductive Medicine
- Ferring Pharmaceuticals and the Chinese Academy of Sciences (CAS) today announced a long-term collaboration to advance basic and translational research in reproductive medicine thr...
2017년 11월 27일
- Ferring Receives Swiss Approval For Rekovelle®, The First Personalised Fertility Treatment Using an Approved Dosing Algorithm
- Ferring Pharmaceuticals announced today that Swissmedic has approved Rekovelle® (follitropin delta) for use in controlled stimulation for induction of the development of multiple f...
2017년 10월 12일
- Ferring Strengthens Growth Hormone Franchise Zomacton® Through Acquisition of ZomaJet™ Needle-Free Injector Device
- Ferring Pharmaceuticals announced today that it has entered into a definitive agreement with Antares Pharma, Inc. to acquire the worldwide rights for the ZomaJet™ needle-free auto ...
2017년 10월 02일
- Ferring Appoints Klaus Dugi as Executive Vice President and Chief Medical Officer
- Ferring Pharmaceuticals announced today that Professor Klaus Dugi has been appointed Executive Vice President and Chief Medical Officer, effective immediately. He will be responsi...
2017년 07월 03일
- Ferring Appoints Lars Peter Brunse to Executive Board
- Ferring Pharmaceuticals announced today that Lars Peter Brunse has been appointed Executive Vice President and Chief Production Officer, and made a member of the Ferring Executive ...
2017년 06월 02일
- Ferring Appoints Aaron Graff to Executive Board
- Ferring Pharmaceuticals announced today that Aaron Graff has been appointed Executive Vice President and Chief Commercial Officer and made a member of the Ferring Group Executive B...
2017년 05월 30일
- World Bedwetting Day Steering Committee: New global guidelines call for more effective treatment for bedwetting, a common condition which affects 1 in 15 children
- The World Bedwetting Day Steering Committee (WBD-SC) has launched simplified practical guidelines to help healthcare professionals understand how best to treat bedwetting. “For de...
2017년 05월 30일
- 세계 야뇨증의 날 운영위원회: 어린이 15명 중 한 명꼴로 발생하는 야뇨증의 효과적인 치료를 촉구하는 새로운 글로벌 가이드라인 제안
- 세계 야뇨증의 날 운영위원회(The World Bedwetting Day Steering Committee, WBD-SC)가 의료 전문가들이 야뇨증의 가장 효율적인 치료법을 이해하는 데 도움을 줄 간소화된 실무 가이드라인을 발표했다. 세르다르 텍귈(Serdar Tek...
2017년 04월 11일
- Ferring Announces Exclusive Agreement with Alrise Biosystems for the Development of an Injectable, Controlled-Release Peptide
- Ferring Pharmaceuticals and Alrise Biosystems announced today that the companies have entered into a development agreement with exclusive option rights for Ferring to leverage Alri...
2017년 04월 07일
- Ferring Highlights Progress on Social and Environmental Goals in Corporate Social Responsibility (CSR) Review 2015-2016
- Ferring Pharmaceuticals releases its second Corporate Social Responsibility (CSR) review, highlighting progress on social and environmental goals in 2015 and 2016 across four key p...
2017년 04월 04일
- Ferring Appoints Dominic Moorhead as Executive Vice President and Chief Financial Officer
- Ferring Pharmaceuticals announced today that Dominic Moorhead has been appointed as Executive Vice President and Chief Financial Officer, effective 1st July 2017. Moorhead succeed...
2017년 03월 17일
- Ferring Pharmaceuticals: Waking up to Go to the Toilet is the Number One Cause of a Poor Night’s Sleep, Say Experts on World Sleep Day
- On World Sleep Day sleep experts encourage people to understand the value of healthy and solid sleep. In particular, if they need to go to the toilet more than once in the night th...
2017년 03월 17일
- 페링제약, 세계 수면의 날에 전문가들에 따르면 야간에 깨어 소변을 보러 가는 일이 수면 방해에 가장 큰 원인
- ‘세계 수면의 날‘(World Sleep Day)에 수면 전문가들이 건강한 숙면의 가치를 이해하라고 격려했다. 특히 야간에 1회 이상 소변을 보러 가는 경우가 야뇨증이며 이는 65세 이상의 성인 2/3와 30세 이상의 성인 3명 중 1명이 영향을 받고 있다. 마...
2017년 02월 13일
- Ferring and Foresee Pharmaceuticals Enter into Exclusive Development and Option Agreement
- Ferring Pharmaceuticals and Foresee Pharmaceuticals Co., Ltd. (6576.TWO), announced today that the companies have entered into an exclusive worldwide development and option agreeme...
2017년 01월 31일
- Ferring Pharmaceuticals and Enteris BioPharma Enter License Agreement to Develop an Oral Formulation of a Peptide-based Injectable Therapeutic
- Ferring Pharmaceuticals and Enteris BioPharma, Inc. announced today that the companies have entered into a license agreement and initiated an early development agreement to leverag...
2016년 12월 20일
- Ferring and IMAB Sign Licensing Agreement Granting IMAB Exclusive Rights in Asia to Olamkicept for the Treatment of Autoimmune Disease
- Ferring Pharmaceuticals and IMAB today announced that they have signed a licensing agreement which grants IMAB exclusive rights to olamkicept (pINN) in Asia. Olamkicept is a new r...
2016년 12월 01일
- Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos Collaborate on Nanotechnology R&D Platform
- Ferring Pharmaceuticals and Aché Laboratórios Farmacêuticos today announced a long-term collaboration aimed at improving the bioavailability, efficacy and safety profile of oral th...
2016년 08월 29일
- Ferring Pharmaceuticals Acquires Exclusive Licensing Rights to Condoliase from Seikagaku Corporation
- Ferring Pharmaceuticals announced today that it has signed an agreement with Seikagaku Corporation granting Ferring the exclusive worldwide rights (excluding Japan) to SI-6603 (con...
2016년 03월 21일
- Ferring Pharmaceuticals: Wake up to Nocturia: the Most Common Cause of Disrupted Sleep That Could Be Damaging Your Health
- Today is ‘World Sleep Day’ which was initiated by the World Association of Sleep Medicine (WASM) to acknowledge the importance of a good night’s sleep and the impact of sleep on he...
2016년 03월 21일
- 페링제약: 야뇨증에 관심 집중: 건강을 해칠 수 있는 수면 장애의 가장 큰 원인
- 오늘은 세계수면학회가 야간 숙면과 수면이 건강 및 삶의 질에 미치는 영향의 중요성을 일깨우기 위해 정한 ‘세계 수면의 날‘(World Sleep Day)이다. 수면 문제는 전세계 인구 중 45%의 건강과 삶의 질을 위협하는 세계적으로 확산된 증상이다. ...
2016년 02월 10일
- Ferring announces the start of the PRONOUNCE Trial for patients with advanced prostate cancer and cardiovascular disease receiving degarelix or leuprolide
- Ferring Pharmaceuticals announced today the commencement of the Phase 3b PRONOUNCE Trial. The trial will compare the occurrence of major adverse cardiovascular events (MACEs) in pa...
2016년 02월 10일
- 페링제약, 데가렐릭스 또는 루프롤라이드를 투약하는 전립선암 및 심혈관질환 환자를 위한 PRONOUNCE 임상시험 시작 공표
- 페링제약(Ferring Pharmaceuticals)이 오늘 3b 단계 PRONOUNCE 임상시험(Phase 3b PRONOUNCE Trial)의 시작을 공표했다. 이 시험에서는 GnRH 수용체 길항제인 데가렐릭스(degarelix)를 투약하는 전립선암 및 심혈관질환 ...
2015년 02월 24일
- Ferring Pharmaceuticals Acquires Novel Drug Delivery Technology From CTCBIO Inc.
- Ferring Pharmaceuticals announced today that it has signed an agreement with CTCBIO Inc. of Seoul, South Korea to acquire rights to a novel oral drug delivery technology. Ferring’...
2015년 02월 23일
- Ferring Pharmaceuticals acquires two phase III ready orthobiologic product candidates from BioSET
- Ferring Pharmaceuticals announced today that it has acquired the assets of BioSurface Engineering Technologies, Inc. (BioSET), including two phase III ready orthobiologic product c...
2015년 02월 02일
- Ferring Pharmaceuticals Moves to Strengthen Growth with Appointment of Chief Medical and Chief Scientific Officers
- Ferring Pharmaceuticals announced today the appointment of Pascal Danglas, MD as Executive Vice President and Chief Medical Officer and Per Falk, MD, PhD as Executive Vice Presiden...